Duality Biotherapeutics (DUTB.F) Stock Overview
A clinical-stage biotech company, discovers and develops antibody-drug conjugate (ADC) therapeutics to treat cancer, autoimmune diseases, and others. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
DUTB.F Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake
Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.Read more
Duality Biotherapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$45.02 |
| 52 Week High | HK$45.05 |
| 52 Week Low | HK$43.69 |
| Beta | 0 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 0% |
Recent News & Updates
Recent updates
Shareholder Returns
| DUTB.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 2.0% | 3.4% |
| 1Y | n/a | 43.3% | 34.6% |
Return vs Industry: Insufficient data to determine how DUTB.F performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how DUTB.F performed against the US Market.
Price Volatility
| DUTB.F volatility | |
|---|---|
| DUTB.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: DUTB.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine DUTB.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2019 | 191 | John Zhu | www.dualitybiologics.com |
Duality Biotherapeutics, Inc., a clinical-stage biotech company, discovers and develops antibody-drug conjugate (ADC) therapeutics to treat cancer, autoimmune diseases, and others. The company provides DB-1303/BNT323, a HER2 ADC candidate targeting cancers, including endometrial cancer1 and breast cancer2; DB-1311/BNT324, a B7-H3 ADC candidate targeting cancers, such as small-cell lung cancer3, castration-resistant prostate cancer4, esophageal squamous cell carcinoma5, and head and neck squamous cell carcinoma; and other clinical-stage ADCs. It has strategic partnerships with BioNTech SE to develop therapies to complement or replace chemotherapy; and BeiGene, Ltd.
Duality Biotherapeutics, Inc. Fundamentals Summary
| DUTB.F fundamental statistics | |
|---|---|
| Market cap | US$4.12b |
| Earnings (TTM) | -US$406.23m |
| Revenue (TTM) | US$311.44m |
Is DUTB.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DUTB.F income statement (TTM) | |
|---|---|
| Revenue | CN¥2.17b |
| Cost of Revenue | CN¥1.36b |
| Gross Profit | CN¥805.86m |
| Other Expenses | CN¥3.64b |
| Earnings | -CN¥2.83b |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -31.66 |
| Gross Margin | 37.13% |
| Net Profit Margin | -130.43% |
| Debt/Equity Ratio | 2.2% |
How did DUTB.F perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/17 20:01 |
| End of Day Share Price | 2025/10/20 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Duality Biotherapeutics, Inc. is covered by 10 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Qianlan Zhu | CGS International |
| Lily Wang | CGS International |
| Lily Wang | China Galaxy International Securities (Hong Kong) |